MEFENAMIC CAPSULE
Riik: Kanada
keel: inglise
Allikas: Health Canada
Toote omadused
(SPC)
10-04-2019
Mõned selle toote dokumendid pole praegu saadaval. Võite saata päringu meie klienditeenindusele ja me teavitame teid sellest niipea, kui meil on neid võimalik hankida.
Saada päring.
Saada päring.
Toimeaine:
MEFENAMIC ACID
Saadav alates:
AA PHARMA INC
ATC kood:
M01AG01
INN (Rahvusvaheline Nimetus):
MEFENAMIC ACID
Annus:
250MG
Ravimvorm:
CAPSULE
Koostis:
MEFENAMIC ACID 250MG
Manustamisviis:
ORAL
Ühikuid pakis:
100/500
Retsepti tüüp:
Prescription
Terapeutiline ala:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Toote kokkuvõte:
Active ingredient group (AIG) number: 0102336001; AHFS:
Volitamisolek:
APPROVED
Loa andmise kuupäev:
2010-12-08
Toote omadused
Page 1 of 32
_ _
PRESCRIBING INFORMATION
PRODUCT MONOGRAPH
PR
MEFENAMIC
MEFENAMIC ACID CAPSULES
250 MG
USP
ANALGESIC
AA PHARMA INC.
1165 CREDITSTONE ROAD, UNIT #1
VAUGHAN, ONTARIO
L4K 4N7
DATE OF REVISION:
April 10, 2019
CONTROL NO.: 226522
Page 2 of 32
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
5
ADVERSE REACTIONS
.................................................................................................
15
DRUG INTERACTIONS
.................................................................................................
16
DOSAGE AND ADMINISTRATION
.............................................................................
19
OVERDOSAGE
...............................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 20
STORAGE AND STABILITY
.........................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
......................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 21
PART II: SCIENTIFIC INFORMATION
...............................................................................
22
PHARMACEUTICAL INFORMATION
.........................................................................
22
CLINICAL TRIALS
.........................................................................................................
23
DETAILED PHARMA
Lugege kogu dokumenti
